GSK‐J4 treatment decreased glioblastoma cell viability in a concentration‐dependent manner, with two cultures expressing high KDM2B levels (4121 and 1587) displaying higher sensitivity compared to glioblastoma cultures expressing low KDM2B levels (T115) and normal astrocytes (Fig. 5A). Here, KDM2B is linked to glioblastoma.